These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20950732)

  • 21. Myelofibrosis with a novel translocation, t(1;3)(q31;q23), and response to imatinib mesylate.
    Yalamanchili K; Liu D; Seiter K
    Leukemia; 2007 Mar; 21(3):577-8. PubMed ID: 17230224
    [No Abstract]   [Full Text] [Related]  

  • 22. Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease.
    Magro F; Costa C
    Inflamm Bowel Dis; 2006 Nov; 12(11):1087-9. PubMed ID: 17075351
    [No Abstract]   [Full Text] [Related]  

  • 23. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.
    Eskazan AE; Ayer M; Kantarcioglu B; Arica D; Demirel N; Aydin D; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
    Br J Haematol; 2014 Oct; 167(1):139-41. PubMed ID: 24815307
    [No Abstract]   [Full Text] [Related]  

  • 24. Imatinib does not impair gonadal function.
    Chuah C
    Leuk Res; 2012 Mar; 36(3):262-3. PubMed ID: 22129479
    [No Abstract]   [Full Text] [Related]  

  • 25. SSc in 2011: From mechanisms to medicines.
    Mouthon L
    Nat Rev Rheumatol; 2012 Jan; 8(2):72-4. PubMed ID: 22231235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases.
    Tamaki Z; Asano Y; Hatano M; Yao A; Kawashima T; Tomita M; Kinugawa K; Nagai R; Sato S
    Mod Rheumatol; 2012 Feb; 22(1):94-9. PubMed ID: 21633912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment for plexiform neurofibromas in patients with NF1.
    Ardern-Holmes SL; North KN
    Lancet Oncol; 2012 Dec; 13(12):1175-6. PubMed ID: 23099008
    [No Abstract]   [Full Text] [Related]  

  • 28. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
    Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
    Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis.
    Haroche J; Amoura Z; Charlotte F; Salvatierra J; Wechsler B; Graux C; Brousse N; Piette JC
    Blood; 2008 Jun; 111(11):5413-5. PubMed ID: 18502845
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension.
    Chhina MK; Nargues W; Grant GM; Nathan SD
    Future Cardiol; 2010 Jan; 6(1):19-35. PubMed ID: 20014985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recurrence of severe pulmonary hypertension following the removal of a lung allograft.
    Grinnan DC; Fairman P; Pinson J
    Chest; 2007 Dec; 132(6):2057-8; author reply 2058. PubMed ID: 18079249
    [No Abstract]   [Full Text] [Related]  

  • 32. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome].
    Menif S; Ben Romdhane N; Hafsia R
    Rev Med Interne; 2008 Jan; 29(1):65-7. PubMed ID: 18036706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome using a tyrosine kinase inhibitor.
    Ascione L; De Michele M; Accadia M; Spadaro P; Rumolo S; Tuccillo B
    Eur J Echocardiogr; 2004 Oct; 5(5):386-90. PubMed ID: 15341874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hits and misses in targeting pediatric cancers.
    Bernstein ML
    Pediatr Blood Cancer; 2009 Jul; 52(7):751-2. PubMed ID: 19185009
    [No Abstract]   [Full Text] [Related]  

  • 35. Is imatinib mesylate a promising drug in systemic sclerosis?
    van Daele PL; Dik WA; Thio HB; van Hal PT; van Laar JA; Hooijkaas H; van Hagen PM
    Arthritis Rheum; 2008 Aug; 58(8):2549-52. PubMed ID: 18668570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib.
    Pitini V; Sturniolo G; Cavallari V; Arrigo C
    Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645
    [No Abstract]   [Full Text] [Related]  

  • 37. Imatinib mesylate (Gleevec™) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial.
    Gordon J; Udeh U; Doobay K; Magro C; Wildman H; Davids M; Mersten JN; Huang WT; Lyman S; Crow MK; Spiera RF
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-189-93. PubMed ID: 25152211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial.
    Prey S; Ezzedine K; Doussau A; Grandoulier AS; Barcat D; Chatelus E; Diot E; Durant C; Hachulla E; de Korwin-Krokowski JD; Kostrzewa E; Quemeneur T; Paul C; Schaeverbeke T; Seneschal J; Solanilla A; Sparsa A; Bouchet S; Lepreux S; Mahon FX; Chene G; Taïeb A
    Br J Dermatol; 2012 Nov; 167(5):1138-44. PubMed ID: 23039171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of imatinib mesylate in a case of Churg-Strauss syndrome: evidence for the pathogenic role of a tyrosine kinase?
    Josselin-Mahr L; Werbrouck-Chiraux A; Garderet L; Cabane J
    Rheumatology (Oxford); 2014 Feb; 53(2):378-9. PubMed ID: 23893665
    [No Abstract]   [Full Text] [Related]  

  • 40. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease.
    Stadler M; Ahlborn R; Kamal H; Diedrich H; Buchholz S; Eder M; Ganser A
    Blood; 2009 Oct; 114(17):3718-9; author reply 3719-20. PubMed ID: 19850751
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.